Plasma concentrations of buprenorphine 24 to 72 hours after dosing

被引:43
作者
Chawarski, MC
Schottenfeld, RS
O'Connor, PG
Pakes, J
机构
[1] Yale Univ, Sch Med, Dept Psychiat, SAC,CMHC, New Haven, CT 06519 USA
[2] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA
关键词
buprenorphine; plasma level; substance abuse; opioid maintenance;
D O I
10.1016/S0376-8716(98)00192-6
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: This study evaluated plasma buprenorphine concentrations 24-72 h following sublingual administration of a dose of buprenorphine solution, ranging from 16 mg/70 kg to 44 mg/70 kg, administered on a daily or thrice-weekly schedule. Additionally, this study evaluated the effects of different thrice-weekly buprenorphine dose schedules on opiate use and withdrawal symptoms. Methods: Opiate dependent subjects (n = 10) were maintained in an outpatient clinic for two 3-week periods at each of three thrice-weekly buprenorphine dose schedules (providing a weekly total buprenorphine dose of 64, 84 and 112 mg) and for 1 week of a daily buprenorphine dose of 16 mg/70 kg. Plasma samples were obtained 24, 48 and 72 h following administration of buprenorphine. Urine samples were also collected and opiate withdrawal symptoms, agonist effects and the use of heroin, cocaine, alcohol and other drugs, were assessed. Results: Plasma levels showed a wide range of intra- and inter-subject variability. Nonetheless, higher doses of buprenorphine resulted in higher plasma concentrations at each time point and plasma concentration decreased with time. There were no significant differences in heroin use across dosing. Rates of withdrawal symptoms were low and did not differ across dosing schedules. Conclusions: In the two highest dose schedules, plasma levels 72 h following the administration of the highest dose and at 48 h after the lower dose, were comparable to plasma concentrations at 24 h following daily administration of 16 mg/70 kg of buprenorphine. (C) 1999 Published by Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:157 / 163
页数:7
相关论文
共 24 条
  • [1] ALTERNATE-DAY DOSING DURING BUPRENORPHINE TREATMENT OF OPIOID DEPENDENCE
    AMASS, L
    BICKEL, WK
    HIGGINS, ST
    BADGER, GJ
    [J]. LIFE SCIENCES, 1994, 54 (17) : 1215 - 1228
  • [2] A CLINICAL-TRIAL OF BUPRENORPHINE - COMPARISON WITH METHADONE IN THE DETOXIFICATION OF HEROIN-ADDICTS
    BICKEL, WK
    STITZER, ML
    BIGELOW, GE
    LIEBSON, IA
    JASINSKI, DR
    JOHNSON, RE
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (01) : 72 - 78
  • [3] BUPRENORPHINE KINETICS
    BULLINGHAM, RES
    MCQUAY, HJ
    MOORE, A
    BENNETT, MRD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (05) : 667 - 672
  • [4] BULLINGHAM RES, 1981, BRIT J CLIN PHARMACO, V12, P117
  • [5] Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients
    Eissenberg, T
    Johnson, RE
    Bigelow, GE
    Walsh, SL
    Liebson, IA
    Strain, EC
    Stitzer, ML
    [J]. DRUG AND ALCOHOL DEPENDENCE, 1997, 45 (1-2) : 81 - 91
  • [6] First M. B., 2016, USERS GUIDE SCID 5 1
  • [7] HAMBROOK JM, 1976, OPIATES ENDOGENOUS O
  • [8] JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501
  • [9] A CONTROLLED TRIAL OF BUPRENORPHINE TREATMENT FOR OPIOID DEPENDENCE
    JOHNSON, RE
    JAFFE, JH
    FUDALA, PJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (20): : 2750 - 2755
  • [10] BUPRENORPHINE TREATMENT OF OPIOID DEPENDENCE - CLINICAL-TRIAL OF DAILY VERSUS ALTERNATE-DAY DOSING
    JOHNSON, RE
    EISSENBERG, T
    STITZER, ML
    STRAIN, EC
    LIEBSON, IA
    BIGELOW, GE
    [J]. DRUG AND ALCOHOL DEPENDENCE, 1995, 40 (01) : 27 - 35